Literature DB >> 15690597

Rheumatoid arthritis market.

Claire Mount, James Featherstone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15690597     DOI： 10.1038/nrd1611

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  7 in total

1.  Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.

Authors:  H-S Lin; C-Y Hu; H-Y Chan; Y-Y Liew; H-P Huang; L Lepescheux; E Bastianelli; R Baron; G Rawadi; P Clément-Lacroix
Journal:  Br J Pharmacol       Date:  2007-02-26       Impact factor: 8.739

2.  Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

Authors:  Chieyeon Chough; Sunmin Lee; Misuk Joung; Jaemin Lee; Jong Hoon Kim; B Moon Kim
Journal:  Medchemcomm       Date:  2018-01-15       Impact factor: 3.597

3.  Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.

Authors:  Tomoko Kawabata; Keiichiro Nishida; Koji Takasugi; Hiroko Ogawa; Kenei Sada; Yasutaka Kadota; Junko Inagaki; Satoshi Hirohata; Yoshifumi Ninomiya; Hirofumi Makino
Journal:  Arthritis Res Ther       Date:  2010-07-07       Impact factor: 5.156

4.  Scavenger Receptor-Mediated Targeted Treatment of Collagen-Induced Arthritis by Dextran Sulfate-Methotrexate Prodrug.

Authors:  Modi Yang; Jianxun Ding; Xiangru Feng; Fei Chang; Yinan Wang; Zhongli Gao; Xiuli Zhuang; Xuesi Chen
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

5.  Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.

Authors:  Jiajiang Xie; Zhongxiong Fan; Yang Li; Yinying Zhang; Fei Yu; Guanghao Su; Liya Xie; Zhenqing Hou
Journal:  Int J Nanomedicine       Date:  2018-03-09

6.  Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo.

Authors:  Zi'ang Xie; Guanxiong Liu; Pan Tang; Xuewu Sun; Shuai Chen; An Qin; Peizhi Zhu; Jianfeng Zhang; Shunwu Fan
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

7.  Methotrexate-loaded nanoparticles ameliorate experimental model of autoimmune arthritis by regulating the balance of interleukin-17-producing T cells and regulatory T cells.

Authors:  Jin-Sil Park; Donghyun Lee; Heebeom Koo; Mi-La Cho; Sung-Hwan Park; SeungCheon Yang; Ha Yeon Jeong; Hyun Sik Na; Keun-Hyung Cho; JeongWon Choi
Journal:  J Transl Med       Date:  2022-02-11       Impact factor: 5.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.